SCHEMBL210793

SCHEMBL210793

O=Cc1ccc(Cn2ccnc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 10/20 0.69
TBXAS1 P24557 5/20 0.66
CYP1A2 P05177 3/20 0.66
CYP3A4 P08684 2/20 0.66
CYP2D6 P10635 2/20 0.66
USP2 O75604 1/20 0.66
LMNA P02545 1/20 0.66
MEN1 O00255 1/20 0.66
CYP2C19 P33261 1/20 0.66
KMT2A Q03164 1/20 0.66
CYP11B2 P19099 8/20 0.66
CYP19A1 P11511 6/20 0.66
CYP2A6 P11509 1/20 0.66
CYP2B6 P20813 1/20 0.66
POLB P06746 1/20 0.62
MAPT P10636 1/20 0.62
QPCT Q16769 1/20 0.62
CYP4Z1 Q86W10 1/20 0.62
QPCTL Q9NXS2 1/20 0.62
CYP17A1 P05093 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzylimidazole SCHEMBL6784009 0.88 CYP11B1 (0.77) CYP11B1TBXAS1CYP1A2CYP3A4CYP2D6
SCHEMBL1024261 0.87 CYP11B1 (0.84) CYP11B1TBXAS1CYP1A2CYP3A4CYP2D6
SCHEMBL29239325 0.86 CYP11B1 (0.66) CYP11B1TBXAS1CYP1A2CYP3A4CYP2D6
SCHEMBL6057476 0.85 CYP11B1 (0.75) CYP11B1TBXAS1CYP1A2CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL1775141 0.85 CYP11B1 (0.81) CYP11B1TBXAS1CYP1A2CYP3A4CYP2D6
SCHEMBL6940691 0.84 CYP11B1 (0.64) CYP11B1TBXAS1CYP1A2CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL28482452 0.83 CYP11B1 (0.62) CYP11B1TBXAS1CYP1A2CYP3A4CYP2D6
SCHEMBL2728383 0.83 CYP11B1 (1.00) CYP11B1CYP11B2
Ethylene SCHEMBL10731121 0.83 CYP11B1 (0.52) CYP11B1TBXAS1CYP1A2CYP3A4CYP2D6
SCHEMBL8405925 0.82 TBXAS1 (0.66) CYP11B1TBXAS1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4041478-A None JP disclosed
CN-118005563-A N-benzyl imidazole derivative and preparation method and application thereof 中国药科大学 2024-05-10 CN disclosed
US-11034780-B2 1,3-dipolar compound bearing an imidazole functional group COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) 2021-06-15 US disclosed
US-11034780-B2 1,3-dipolar compound bearing an imidazole functional group COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) 2021-06-15 US disclosed
EP-3060552-B1 1,3-DIPOLAR COMPOUND BEARING AN IMIDAZOLE FUNCTION AND PROCESS FOR MODIFYING AN UNSATURATED POLYMER BY GRAFTING MICHELIN & CIE (FR) 2020-12-02 EP disclosed
EP-3060552-B1 1,3-DIPOLAR COMPOUND BEARING AN IMIDAZOLE FUNCTION AND PROCESS FOR MODIFYING AN UNSATURATED POLYMER BY GRAFTING MICHELIN & CIE (FR) 2020-12-02 EP disclosed
US-20190119412-A1 1,3-DIPOLAR COMPOUND BEARING AN IMIDAZOLE FUNCTIONAL GROUP MICHELIN & CIE (FR) 2019-04-25 US disclosed
US-20190119412-A1 1,3-DIPOLAR COMPOUND BEARING AN IMIDAZOLE FUNCTIONAL GROUP MICHELIN & CIE (FR) 2019-04-25 US disclosed
US-10202471-B2 1,3-dipolar compound bearing an imidazole functional group COMPAGNIE GENERALE DES ETABLISSMENTS MICHELIN (FR) 2019-02-12 US disclosed
US-10202471-B2 1,3-dipolar compound bearing an imidazole functional group COMPAGNIE GENERALE DES ETABLISSMENTS MICHELIN (FR) 2019-02-12 US disclosed
EP-1963315-A2 ENZYME INHIBITORS The Institute of Cancer Research (GB) 2008-09-03 EP disclosed
WO-2007072017-A2 ENZYME INHIBITORS THE INSTITUTE OF CANCER RESEARCH (GB) 2007-06-28 WO disclosed
EP-0784612-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-07-23 EP disclosed
WO-1996010559-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-04-11 WO disclosed
US-5286869-A Vasodilators and anticoagulants FUJIREBIO KABUSHIKI KAISHA (JP) 1994-02-15 US disclosed
JP-H0441478-A PRODUCTION OF 3-(4-1-IMIDAZOLYLMETHYL)PHENYL)-2-PROPENE-1-OL FUJIREBIO INC 1992-02-12 JP disclosed
EP-0320984-A2 1,4-Dihydropyridine derivatives FUJIREBIO INC. (JP) 1989-06-21 EP disclosed
EP-0169408-B1 IMIDAZOLYL COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS DRUGS HOECHST AKTIENGESELLSCHAFT (DE) 1989-05-31 EP disclosed
US-4665080-A THROMBOXANE SYNTHETASE INHIBITORS HOECHST AKTIENGESELLSCHAFT (DE) 1987-05-12 US disclosed
EP-0169408-A1 Imidazolyl compounds, process for their preparation and their use as drugs HOECHST AKTIENGESELLSCHAFT (DE) 1986-01-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202471-B2 1,3-dipolar compound bearing an imidazole functional group TBCB, CCNB1, H1-0 CYP11B1 1013/4885TBXAS1 204/4885CYP1A2 1143/4885
US-11034780-B2 1,3-dipolar compound bearing an imidazole functional group TBCB, CCNB1, H1-0 CYP11B1 1013/4885TBXAS1 204/4885CYP1A2 1143/4885
US-20190119412-A1 1,3-DIPOLAR COMPOUND BEARING AN IMIDAZOLE FUNCTIONAL GROUP TBCB, CCNB1, H1-0 CYP11B1 1013/4885TBXAS1 204/4885CYP1A2 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.